Evidence map›Paper›PMID 38332153›Full record

ArticleEMBO reports2024

TGFβ-induced long non-coding RNA LINC00313 activates Wnt signaling and promotes cholangiocarcinoma.

Panagiotis Papoutsoglou, Raphaël Pineau, Raffaële Leroux, Corentin Louis, Anaïs L'Haridon, Dominika Foretek, Antonin Morillon, Jesus M Banales, David Gilot, Marc Aubry and 1 more

Open access · diamondAbstract read
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.International journal of medical sciences · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Linc00513 sponges miR-7 to modulate TGF-β signaling in azoospermia.European journal of translational myology · 2024
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Panagiotis PapoutsoglouInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.ORCID 0000-0003-2115-3500
Raphaël PineauInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.
Raffaële LerouxInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.
Corentin LouisInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.
Anaïs L'HaridonInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.
Dominika ForetekncRNA, Epigenetic and Genome Fluidity, CNRS UMR3244, Sorbonne University, PSL University, Institut Curie, Centre de Recherche, Paris, France.
Antonin MorillonncRNA, Epigenetic and Genome Fluidity, CNRS UMR3244, Sorbonne University, PSL University, Institut Curie, Centre de Recherche, Paris, France.ORCID 0000-0002-0575-5264
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute, Donostia University Hospital, CIBERehd, Ikerbasque, San Sebastian, Spain.ORCID 0000-0002-5224-2373
David GilotInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.ORCID 0000-0002-2646-671X
Marc AubryInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France.ORCID 0000-0002-6954-8141
Cédric CoulouarnInserm, Univ Rennes, OSS (Oncogenesis, Stress, Signaling) laboratory, UMR_S 1242, Centre de Lutte contre le Cancer Eugène Marquis, F-35042, Rennes, France. cedric.coulouarn@inserm.fr.ORCID 0000-0002-5692-9586
Inserm · FRCentre National de la Recherche Scientifique · FRUniversidad Publica de Navarra · ES

Funding

AMMF-The Cholangiocarcinoma Charity EU/2019/AMMFt/001Conseil Régional de Bretagne (Brittany Council) PhD fellowshipEuropean Union Horizon 2020 Research and Innovation Program 825510/ESCALONFondation ARC pour la Recherche sur le Cancer (ARC) R21043NNFrench Ministry of Health and the French National Cancer Institute, PRT-K20-136, CHU Rennes, CLCC Eugene Marquis, Rennes R21095NNINCa and ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé) dans le cadre du Plan cancer (Non-coding RNA in cancerology: fundamental to translational) C18007NS,C20013NS,C20014NSInstitut National de la Santé et de la Recherche Médicale (Inserm) Recurrent FundingInstitut National Du Cancer (INCa) EU TRANSCAN23-002-2023-129,INCa_18688'la Caixa' Foundation ('la Caixa') HR17-00601Ligue Contre le Cancer (French League Against Cancer) R22026NN,R21011NNPSC Partners US and PSC Supports UK 06119JBSpanish Carlos III Health Institute (ISCIII) [(FIS PI18/01075, PI21/00922, and Miguel Servet Programme CPII19/00008) cofinanced by "Fondo Europeo de Desarrollo Regional" (FEDER)] and CIBERehd (ISCIII) FIS PI18/01075,PI21/00922,CPII19/00008Université de Rennes 1 (University of Rennes 1) Recurrent Funding,PhD felloship
6 · The paper itself

Abstract

Cholangiocarcinoma is a devastating liver cancer characterized by high aggressiveness and therapy resistance, resulting in poor prognosis. Long non-coding RNAs and signals imposed by oncogenic pathways, such as transforming growth factor β (TGFβ), frequently contribute to cholangiocarcinogenesis. Here, we explore novel effectors of TGFβ signalling in cholangiocarcinoma. LINC00313 is identified as a novel TGFβ target gene. Gene expression and genome-wide chromatin accessibility profiling reveal that nuclear LINC00313 transcriptionally regulates genes involved in Wnt signalling, such as the transcriptional activator TCF7. LINC00313 gain-of-function enhances TCF/LEF-dependent transcription, promotes colony formation in vitro and accelerates tumour growth in vivo. Genes affected by LINC00313 over-expression in CCA tumours are associated with KRAS and TP53 mutations and reduce overall patient survival. Mechanistically, ACTL6A and BRG1, subunits of the SWI/SNF chromatin remodelling complex, interact with LINC00313 and affect TCF7 and SULF2 transcription. We propose a model whereby TGFβ induces LINC00313 in order to regulate the expression of hallmark Wnt pathway genes, in co-operation with SWI/SNF. By modulating key genes of the Wnt pathway, LINC00313 fine-tunes Wnt/TCF/LEF-dependent transcriptional responses and promotes cholangiocarcinogenesis.

Indexed as

CholangiocarcinomaRNA, Long NoncodingActinsChromosomal Proteins, Non-HistoneDNA-Binding ProteinsHumansTranscription FactorsTransforming Growth Factor betaWnt Signaling PathwayActinsACTL6A protein, humanChromosomal Proteins, Non-HistoneDNA-Binding ProteinsRNA, Long NoncodingTranscription FactorsTransforming Growth Factor betaCholangiocarcinomaChromatin RemodellinglncRNATGFβ SignallingWnt Pathway

Identifiers

PMID38332153
PMCPMC10933437
OpenAlexW4391645209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.